Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
about
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysisSiltuximab (CNTO 328): a promising option for human malignanciesReview of health-related quality of life data in multiple myeloma patients treated with novel agents.Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapyA dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.Novel proteasome inhibitors to overcome bortezomib resistance.Bortezomib for previously untreated multiple myeloma.A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.Overcoming bortezomib resistance in multiple myeloma.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsA historical perspective on milestones in multiple myeloma research.
P2860
Q26991817-93B31C10-7816-4B9F-9A3B-76B0037CEB6DQ28082572-A9591A47-18D6-4456-9E77-7C7C18438BC3Q30650394-352D3DF8-E706-40CE-8780-FDF548E0DA9DQ33431175-724108DF-F3C0-476D-80F0-D81C0ABF97FDQ33882439-ECAFD155-75DE-46CC-9869-7B0B428AB1DDQ34195083-C31BBC8B-A7BF-4884-A26A-E38A8AF021EEQ36216250-8FB21421-C17B-417F-9347-BB68A0174467Q36251560-DCB26C4D-5F36-4B57-9103-5A190D3F6AD4Q36356398-B2A9832F-50A7-4874-9B9B-785AE3AA0ABCQ37878771-22B14DF9-9699-48D6-85EC-C58DCD3CE5CCQ37908155-FB09A516-CCB8-4933-AF48-37307D5E73B6Q38066137-38D98BCC-2900-491A-BC72-6CBC17B77392Q38155425-12AF573A-938D-4B41-8932-583DA944314AQ38176293-CFE2C1A8-68F5-4B65-83E9-4322B85B72D2Q38238610-896A5CE1-3943-4B6E-9068-C3E11FB8851BQ38246060-0A4C2971-B0C0-44D9-B7D5-EFAC6B1C616EQ38261677-9C6655F0-A325-4D05-884C-4BC0E2D4B35DQ38932086-BC157BBA-60D5-4431-A31D-302DBC93FDB1Q39569161-727306CE-A854-4525-B409-2A5AFB9A9D21Q41583227-DB36873F-6B21-4533-AC51-6BCB3AA93DFAQ41620033-B2517C12-4381-40CB-A6C3-176007D7EB02Q48196787-832A6B34-33F9-4CF7-A08E-BD2479969F05
P2860
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@ast
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@en
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@nl
type
label
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@ast
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@en
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@nl
prefLabel
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@ast
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@en
Primary therapy with single ag ...... sults of the ECOG E2A02 trial.
@nl
P2093
P2860
P356
P1433
P1476
Primary therapy with single ag ...... esults of the ECOG E2A02 trial
@en
P2093
D H Vesole
N Callandar
P R Greipp
P2860
P2888
P304
P356
10.1038/LEU.2010.129
P577
2010-06-10T00:00:00Z
P5875
P6179
1029131028